CDKN2A and cancer: This study used a larger sample of different teams from different backgrounds to ensure that the results of the study could be generalized and to highlight the potential value of CDKN2A ALT as a predictive biomarker of response to ICIs, which can have implications for the personalization of cancer immunotherapy.